Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fleroxacin overview

K G Naber1

  • 1Department of Urology, University of Munich Medical School, Elisabeth Hospital, Straubing, Germany.

Chemotherapy
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Fleroxacin, a trifluorinated 4-quinolone antibiotic, effectively treats various bacterial infections by inhibiting DNA gyrase. Its broad spectrum, excellent bioavailability, and once-daily dosing make it a versatile option for common and complex infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linguistic validation and cognitive assessment of the French version of the Acute Cystitis Symptom Score questionnaire.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

Additional assessment of Acute Cystitis Symptom Score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II.

World journal of urology·2019
Same author

[Urogenital tuberculosis and schistosomiasis (bilharzia) : Urological challenges in displaced persons].

Der Urologe. Ausg. A·2018
Same author

Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiologic eradication: a noncomparative, prospective observational study.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

[Are there alternatives to antimicrobial therapy and prophylaxis of uncomplicated urinary tract infections?]

Urologiia (Moscow, Russia : 1999)·2017
Same author

[New questionnaire for the German validation of the Acute Cystitis Symptom Score].

Der Urologe. Ausg. A·2017
Same journal

Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy.

Chemotherapy·2026
Same journal

Pseudoprogression of a head and neck cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy: a case report and review of the literature.

Chemotherapy·2026
Same journal

Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case series.

Chemotherapy·2026
Same journal

Efficacy and Safety Study of Different Doses of Linezolid in Combination with Bedaquiline in the Treatment of Drug-Resistant Pulmonary Tuberculosis.

Chemotherapy·2026
Same journal

Can Model-Informed Precision Dosing of Beta-Lactams in Critical Care Improve Clinical Outcomes?

Chemotherapy·2026
Same journal

Expression of Concern.

Chemotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Fleroxacin is a novel trifluorinated 4-quinolone antibiotic.
  • It functions by inhibiting the bacterial enzyme DNA gyrase, crucial for DNA replication.

Purpose of the Study:

  • To evaluate the efficacy and pharmacokinetic profile of fleroxacin.
  • To determine appropriate dosages for various bacterial infections.

Main Methods:

  • Administration of oral and intravenous fleroxacin.
  • Assessment of antibacterial spectrum, bioavailability, tissue penetration, and half-life.
  • Clinical evaluation in patients with uncomplicated and complicated infections.

Main Results:

  • Broad-spectrum activity against aerobic gram-negative and gram-positive bacteria, including staphylococci.

Related Experiment Videos

  • Excellent bioavailability, high plasma/tissue concentrations, and a 10-12 hour half-life.
  • Effective single-dose treatment for uncomplicated cystitis, gonococcal infections, enteritis, and traveler's diarrhea.

    • Conclusions:

    • Fleroxacin demonstrates efficacy in treating a range of bacterial infections.
    • Once-daily administration is feasible due to its favorable pharmacokinetic properties.
    • Dosage adjustments may be necessary for complicated urinary tract infections and pyelonephritis.